# Beta-lactam Intermittent Versus Continuous Infusion and Combination Antibiotic Therapy in Sepsis

> **NCT05681442** · PHASE4 · RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 600 (estimated)

## Conditions studied

- Sepsis

## Interventions

- **DRUG:** continuous pivotal βL-AB
- **DRUG:** intermittent pivotal βL-AB
- **DRUG:** AG infusion most 1 dose
- **DRUG:** AG infusion for 5 days

## Key facts

- **NCT ID:** NCT05681442
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-13
- **Primary completion:** 2027-01-04
- **Final completion:** 2027-06-04
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05681442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05681442, "Beta-lactam Intermittent Versus Continuous Infusion and Combination Antibiotic Therapy in Sepsis". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT05681442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*